Article
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
All News
Article
Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive impairment.
Article
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Article
A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus. The goal of treatment in SLE is aimed at remission or low disease activit
Dr. John Cush
Tweet
Perspectives on TNFi: Dr. Jon Giles
Dr. Jon Giles offers his perspective and insight into data presented Saturday at #ACR21 annual meeting, specifically abstract #0457.
https://t.co/efIGP5HDUQ https://t.co/2oXkcLC028
Dr. John Cush
Tweet
Psoriatic Arthritis: "What Matters" to Patients, Physicians
Dr. Swetha Ann Alexander ( @swethaann23 ) shares a summary of a poster from #ACR21 discussing what matters to patients and physicians when assessing psoriatic arthritis.
https://t.co/RPTmOeasUp https://t.co/K9oCpcvmKx
Dr. John Cush
Tweet
After failing a JAK inhibitor, can you still hit a JAK-pot?
Dr. Eric Dein ( @ericdeinmd) summarizes the abstracts presented at #ACR21.
https://t.co/qRM7daiBmh https://t.co/yM0pT091i9
Dr. John Cush
Tweet
#ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2021 Day 2.
https://t.co/Q6jCm29MN0 https://t.co/RTiifs5GxA
Dr. John Cush
Tweet
Management of Pain in Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0360 presented at the #ACR21 annual meeting.
https://t.co/C6QU1J6E18 https://t.co/EAfXarQ976
Dr. John Cush
Tweet
Iberdomide for Lupus: Dr. Kathryn Dao ( @KDAO2011 ) discusses abstract #1458 presented at the #ACR21 annual meeting.
https://t.co/viLtTG0tzB https://t.co/rdWTXaquDS
Dr. John Cush
Tweet
JAKi For Refractory Still’s Disease: Dr. Olga Petryna ( @DrPetryna) discusses abstract #0195 presented at the #ACR21 annual meeting.
https://t.co/deSxncZOVP https://t.co/OJWGd4Osc4
Dr. John Cush
Tweet
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Pedro Castillo
Tweet
Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo)
🔹Prior-TNF vs TNF-naive: similar
Significant improvement:
🔹ACR 20/50/70 & HAQ-DI
🔹TJC/SJC/enthesitis
https://t.co/RV1zLpkUQe
#ACR21 Abst#1820 @RheumNow
Pedro Castillo
Tweet
Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24.
🔹Randomized 173 pts
🔹52 weeks
🔹1° met
(continued below)
https://t.co/65ZXDjG9ur
#ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8
Pedro Castillo
Tweet
Glucocorticoids (GC) in SLE on Belimumab
🔹Post-hoc, 5 phase 3 trials
🔹1° endpoint >25% pred↘️ to <7.5mg/d
🔹BEL n=1869; Placebo n=1217
🔹Baseline: 88% on GC; mean ~12.3mg/d pred
🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024)
https://t.co/xp9LamlpHZ
#ACR21 Abst#1283 @RheumNow
sheila
Tweet
#ICYMI #ACR21
Watch my interview with @LatikaGupta_ as she discusses the CoVAD study.
@RheumNow @APLAR_org @rheumarhyme https://t.co/et0X7ltx3K
Nouf Al hemmadi
Tweet
The amazing team @RheumNow and Dr.Kavanaugh are reviewing abstracts. #ACR21
https://t.co/kz8Y5mEgPN https://t.co/n0NMQ0P9uU
TheDaoIndex
Tweet
My Interview with Dr. Seoyoung Kim
👉🏼why/how she got into research
👉🏼her studies on CV risk w/HCQ, real world evidence CV risk w/Tofacitinib, gout T2T MACE occurrence @rheumnow #acr21
https://t.co/RjW5yfyWF6 via @YouTube
Dr. John Cush
Tweet
Day 1 Report from #ACR21
The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations.
https://t.co/hhuGBe8dwr https://t.co/I5dCzFd9SJ
Pedro Castillo
Tweet
Dr. Dellaripa w/great talk on digital ischemia.
Presents case of 25 yo F w/SLE, Class IV LN, APS, on apixaban, MMF, HCQ admitted w/AKI, ⬆️Upro & U-blood
-> new HFrEF (EF 22%), tachy, & digital ischemia w/skin bx = thrombotic vasculopathy.
#ACR21 Scientific Session 9T114 @RheumNow
